3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
1
Lymphopenia
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
COVID-19
1
Interventions
Standard of Care
2
COVID-19 Vaccines
2
regorafenib
1
proxalutamide
1
palbociclib
1
cilgavimab and tixagevimab drug combination
1
bemcentinib
1
acalabrutinib
1
Sorafenib
1
Sodium Chloride
1
Rabeprazole
1
NVX-CoV2373 adjuvated lipid nanoparticle
1
Janus Kinase Inhibitors
1
Interleukin-7
1
IBIO123
1
Gelsolin
1
COH04S1 COVID-19 vaccine
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
2019-nCoV Vaccine mRNA-1273
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
COVID-19
×
Interleukin-7
×
Clear all
NCT04426201
2024-04-11
ILIAD-7-US-O
Revimmune
Phase 2
Terminated
10 enrolled